280 related articles for article (PubMed ID: 27744392)
21. The safety of iloprost in systemic sclerosis in a real-life experience.
Bellando-Randone S; Bruni C; Lepri G; Fiori G; Bartoli F; Conforti ML; Moggi-Pignone A; Guiducci S; Giuggioli D; Colaci M; Spinella A; Ferri C; Matucci-Cerinic M
Clin Rheumatol; 2018 May; 37(5):1249-1255. PubMed ID: 29470737
[TBL] [Abstract][Full Text] [Related]
22. Practical suggestions on intravenous iloprost in Raynaud's phenomenon and digital ulcer secondary to systemic sclerosis: Systematic literature review and expert consensus.
Ingegnoli F; Schioppo T; Allanore Y; Caporali R; Colaci M; Distler O; Furst DE; Hunzelmann N; Iannone F; Khanna D; Matucci-Cerinic M
Semin Arthritis Rheum; 2019 Feb; 48(4):686-693. PubMed ID: 29706243
[TBL] [Abstract][Full Text] [Related]
23. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension.
McLaughlin VV; Oudiz RJ; Frost A; Tapson VF; Murali S; Channick RN; Badesch DB; Barst RJ; Hsu HH; Rubin LJ
Am J Respir Crit Care Med; 2006 Dec; 174(11):1257-63. PubMed ID: 16946127
[TBL] [Abstract][Full Text] [Related]
24. [Digital ulcers in systemic sclerosis : A retrospective heath service study analysing treatment with bosentan and other vasoactive therapies].
Riemekasten G; Beissert S; Distler JH; Kreuter A; Müller-Ladner U
Z Rheumatol; 2017 Apr; 76(3):228-237. PubMed ID: 27535277
[TBL] [Abstract][Full Text] [Related]
25. Iloprost enhances portal flow velocity and volume in patients with systemic sclerosis.
Zardi EM; Picardi A; Ambrosino G; Fazio VM; Dobrina A; Frego M; Afeltra A; Lumachi F
In Vivo; 2006; 20(3):377-80. PubMed ID: 16724674
[TBL] [Abstract][Full Text] [Related]
26. Possible role of iloprost (stable analog of PG12) in promoting neoangiogenesis in systemic sclerosis.
Faggioli P; Giani L; Mazzone A
Clin Exp Rheumatol; 2006; 24(2):220-1. PubMed ID: 16762173
[No Abstract] [Full Text] [Related]
27. Systemic sclerosis therapy with iloprost: a prospective observational study of 30 patients treated for a median of 3 years.
Bettoni L; Geri A; Airò P; Danieli E; Cavazzana I; Antonioli C; Chiesa L; Franceschini F; Grottolo A; Zambruni A; Radaeli E; Cattaneo R
Clin Rheumatol; 2002 Jun; 21(3):244-50. PubMed ID: 12111631
[TBL] [Abstract][Full Text] [Related]
28. Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil.
Launay D; Sitbon O; Le Pavec J; Savale L; Tchérakian C; Yaïci A; Achouh L; Parent F; Jais X; Simonneau G; Humbert M
Rheumatology (Oxford); 2010 Mar; 49(3):490-500. PubMed ID: 20015974
[TBL] [Abstract][Full Text] [Related]
29. Bosentan improves exercise tolerance and Tei index in patients with pulmonary hypertension and prostanoid therapy.
Seyfarth HJ; Pankau H; Hammerschmidt S; Schauer J; Wirtz H; Winkler J
Chest; 2005 Aug; 128(2):709-13. PubMed ID: 16100158
[TBL] [Abstract][Full Text] [Related]
30. Retrospective analysis of the frequency of centrofacial telangiectasia in systemic sclerosis patients treated with bosentan or ilomedin.
Hetzer S; Buhren BA; Schrumpf H; Bölke E; Meller S; Kammers K; Gerber PA; Homey B
Eur J Med Res; 2014 Jan; 19(1):2. PubMed ID: 24410934
[TBL] [Abstract][Full Text] [Related]
31. Association between nailfold capillaroscopy findings and pulmonary function tests in patients with systemic sclerosis.
Castellví I; Simeón-Aznar CP; Sarmiento M; Fortuna A; Mayos M; Geli C; Diaz-Torné C; Moya P; De Llobet JM; Casademont J
J Rheumatol; 2015 Feb; 42(2):222-7. PubMed ID: 25399393
[TBL] [Abstract][Full Text] [Related]
32. Bosentan in clinical practice for treating digital and other ischemic ulcers in Spanish patients with systemic sclerosis: IBER-DU cohort study.
Roman Ivorra JA; Simeon CP; Alegre Sancho JJ; Egurbide MV; Castillo MJ; Lloria X; Fonollosa V
J Rheumatol; 2011 Aug; 38(8):1631-5. PubMed ID: 21632679
[TBL] [Abstract][Full Text] [Related]
33. Survival of patients with idiopathic pulmonary arterial hypertension after listing for transplantation: impact of iloprost and bosentan treatment.
Dandel M; Lehmkuhl HB; Mulahasanovic S; Weng Y; Kemper D; Grauhan O; Knosalla C; Hetzer R
J Heart Lung Transplant; 2007 Sep; 26(9):898-906. PubMed ID: 17845928
[TBL] [Abstract][Full Text] [Related]
34. Long-term clinical stabilization of scleroderma patients treated with a chronic and intensive IV iloprost regimen.
Foti R; Visalli E; Amato G; Benenati A; Converso G; Farina A; Bellofiore S; Mulè M; Di Gangi M
Rheumatol Int; 2017 Feb; 37(2):245-249. PubMed ID: 27796521
[TBL] [Abstract][Full Text] [Related]
35. Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon. A randomized, controlled study.
Scorza R; Caronni M; Mascagni B; Berruti V; Bazzi S; Micallef E; Arpaia G; Sardina M; Origgi L; Vanoli M
Clin Exp Rheumatol; 2001; 19(5):503-8. PubMed ID: 11579708
[TBL] [Abstract][Full Text] [Related]
36. Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids.
Hoeper MM; Taha N; Bekjarova A; Gatzke R; Spiekerkoetter E
Eur Respir J; 2003 Aug; 22(2):330-4. PubMed ID: 12952269
[TBL] [Abstract][Full Text] [Related]
37. Nailfold Videocapillaroscopic Features and Other Clinical Risk Factors for Digital Ulcers in Systemic Sclerosis: A Multicenter, Prospective Cohort Study.
Cutolo M; Herrick AL; Distler O; Becker MO; Beltran E; Carpentier P; Ferri C; Inanç M; Vlachoyiannopoulos P; Chadha-Boreham H; Cottreel E; Pfister T; Rosenberg D; Torres JV; Smith V;
Arthritis Rheumatol; 2016 Oct; 68(10):2527-39. PubMed ID: 27111549
[TBL] [Abstract][Full Text] [Related]
38. Role of iloprost and bosentan in pulmonary arterial hypertension.
Saleh JA
Niger J Med; 2008; 17(1):13-9. PubMed ID: 18390125
[TBL] [Abstract][Full Text] [Related]
39. Digital ulcers and outcomes assessment in scleroderma.
Matucci-Cerinic M; Seibold JR
Rheumatology (Oxford); 2008 Oct; 47 Suppl 5():v46-7. PubMed ID: 18784143
[TBL] [Abstract][Full Text] [Related]
40. Reduced perfusion in systemic sclerosis digital ulcers (both fingertip and extensor) can be increased by topical application of glyceryl trinitrate.
Hughes M; Moore T; Manning J; Wilkinson J; Dinsdale G; Roberts C; Murray A; Herrick AL
Microvasc Res; 2017 May; 111():32-36. PubMed ID: 28027937
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
